Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBU-CHIP: Albumin + Ringer Lactate vs Ringer Lactate During Cytoreductive Surgery with HIPEC
2024-510943-76-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albumin (human) in peritoneal carcinomatosis (PC), gastrointestinal neoplasia and Gynecological neoplasia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Comprehensive Complication Index at day 28. Planned start Mar 2025; status: authorised.
02
Drugs
albumin (human)
03
Conditions
peritoneal carcinomatosis (PC)gastrointestinal neoplasiaGynecological neoplasia
Beyond the preview
Go deeper on 2024-510943-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510943-76-00.